After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, IONS falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Ionis Pharmaceuticals Inc is $6.33B. A total of 2.46 million shares were traded on the day, compared to an average of 1.70M shares.
In the most recent transaction, Hayden Michael R bought 15,000 shares of IONS for 31.86 per share on May 01 ’25. After the transaction, the Director now owns 50,219 company shares. In a previous transaction on Apr 16 ’25, Birchler Brian sold 680 shares at 28.37 per share. IONS shares that EVP, Corp and Development Ops owns now total 56,660.
Among the insiders who sold shares, Jenne Kyle disposed of 3,016 shares on Apr 16 ’25 at a per-share price of $28.36. This resulted in the EVP, Chf GL Pdt Str Ofcr holding 11,199 shares of IONS after the transaction. In another insider transaction, Baroldi Joseph sold 3,928 shares at $28.40 per share on Apr 16 ’25. Company shares held by the EVP, Chief Business Officer now total 31,926.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, IONS has a high of $52.34 and a low of $23.95.
As of this writing, IONS has an earnings estimate of $0.13 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of $0.61 per share and a lower estimate of -$0.45.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. IONS’s latest balance sheet shows that the firm has $2.11B in Cash & Short Term Investments as of fiscal 2021. There were $1.25B in debt and $240.55M in liabilities at the time. Its Book Value Per Share was $2.99, while its Total Shareholder’s Equity was $771.74M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IONS is Buy with a score of 4.13.
